GSK settles vast majority of Zantac claims for $2.2 billion
GSK has struck a $2.2 billion agreement to settle the vast majority of U.S. lawsuits filed against it over claims its Zantac ...
Reuters on MSN1mon
GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2 billion
(Reuters) -GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued ...
FierceBiotech28d
GSK's depemokimab reduces polyps in phase 3 trials, adding weight to upcoming filing
GSK’s blockbuster hopes for depemokimab remain on track after the investigational long-acting asthma treatment has also been shown to reduce nasal polyps in a pair of phase 3 trials. The ANCHOR ...
Yahoo Finance28d
GSK Says Depemokimab For Chronic Rhinosinusitis Reduces Nasal Polyp Size, Nasal Obstruction Versus Placebo At One Year
On Monday, GSK plc (NYSE:GSK) released headline results from the phase 3 trials ANCHOR-1 and ANCHOR-2, which assessed the efficacy and safety of depemokimab versus placebo in adults with chronic ...
FierceBiotech12d
GSK axes vaccine from $2.1B deal, switching to preclinical successor over 'increased competition'
GSK has stopped (PDF) development of one of the lead programs from its $2.1 billion Affinivax takeover, axing a phase 2 pneumococcal 24-valent vaccine candidate for adults in favor of a ...